

Cue Biopharma to Host Business Update Call and Webcast

March 9, 2021

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- <u>Cue Biopharma, Inc.</u> (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a business update on Tuesday, March 16, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's <u>website</u>.

Members of the Cue Biopharma executive management team will provide clinical updates on the Company's ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA[®] (pembrolizumab) as first-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company's most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.

Tuesday, March 16 at 4:30 p.m. EDT

 Investors:
 877-407-9208

 International:
 201-493-6784

 Conference ID:
 13716744

Webcast: http://public.viavid.com/index.php?id=143645

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT TM (Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor Contact

George B. Zavoico, Ph.D. VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media Contact

Darren Opland, Ph.D. LifeSci Communications darren@lifescicomms.com



Source: Cue Biopharma, Inc.